research use only
Cat.No.S4096
| Related Targets | Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR |
|---|---|
| Other Dopamine Receptor Inhibitors | MPTP Hydrochloride Trifluoperazine Trifluoperazine 2HCl Penfluridol Sulpiride SCH-23390 hydrochloride Levosulpiride Domperidone SKF38393 HCl Rotundine |
|
In vitro |
DMSO
: 76 mg/mL
(200.3 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 379.43 | Formula | C22H22FN3O2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 548-73-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NSC 169874,Dehydrobenzperidol | Smiles | C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F | ||
| In vitro |
Droperidol produces mild α-adrenergic blockade and peripheral vascular dilation. This compound has been shown to block potassium efflux in the myocardium in isolated animal ventricular myocytes, resulting in a dose-dependent delay in repolarization. It has also been shown to induce early depolarizations in isolated animal Purkinje fibers. |
|---|---|
| In vivo |
Droperidol (0.01 mM-0.3 mM) increases in a dose-dependent fashion action potential duration (APD) without altering the other parameters in rabbit Purkinje fibers stimulated at 60 pulses/min. This compound (1 mM-3 mM) leads to the reversal of the prolonging effect in rabbit Purkinje fibers. It (10 mM-30 mM) produces shortening in APD at 50% repolarization concomitantly with a significant decrease in Vmax, action potential amplitude and resting membrane potential in rabbit Purkinje fibers. This chemical exerts a dual effect on repolarization, prolongation with low concentrations with development of EADs and subsequent triggered activity in rabbit Purkinje fibers. It (3 mg/kg, single dose) decreases dose dependently not only locomotion and rearing frequencies in the open-field but also the apomorphine effects of rats. This compound (3 mg/kg, long term administration) induces significant tolerance to all parameters of activity recorded in the open-field in rats. This chemical withdrawn produces an augmented responsiveness to apomorphine-induced stereotyped behavior. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05759481 | Recruiting | Post-operative Nausea and Vomiting |
Milton S. Hershey Medical Center |
February 1 2024 | Phase 2 |
| NCT05244460 | Recruiting | Cannabis Hyperemesis Syndrome |
Mercy Health Ohio|Lake Erie College of Osteopathic Medicine |
December 2 2021 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.